ライブ
PharmaVoiceCompetition is brewing between ADCs and bispecificsPromega BlogThe Hidden Switch That Controls Lysosome FunctionFierceBiotechCardiovascular-focused Kardigan plans to bring in cozy $320M haul from upcoming IPOFierceBiotechCaribou boosts case that off-the-shelf CAR-T matches autologous drugs ahead of phase 3CellDNA repair drives cisplatin-induced neuronal deathCellLong-term reversal of Duchenne muscular dystrophy via circular arRNA-guided exon skipping in monkeys and humansCellPersistent and transient senescent cells contribute to brain-barrier developmentCellContinuous modeling of primate embryogenesis from totipotency to early organogenesisCellRNA structure programs endogenous ADAR for precise and efficient editingFierceBiotech‘I’m a lot more optimistic today’: Mike Doustdar tells Fierce about pivotal first year as Novo Nordisk CEOFierceBiotechTakeda’s TYK2 inhibitor beats Bristol Myers’ Sotyktu in phase 3 psoriasis showdownEndpoints NewsTakeda's plaque psoriasis pill beats Bristol Myers' Sotyktu in Phase 3
Recursion 2026年4月24日

AI-Driven Target Discovery Breakthrough Might Change The Case For Investing In Recursion Pharmaceuticals (RXRX) - simplywall.st

AI-Driven Target Discovery Breakthrough Might Change The Case For Investing In Recursion Pharmaceuticals (RXRX) - simplywall.st

原文
本文は利用できません。元の情報源をご確認ください。